γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)(1,2). Here, in contrast to other cancer types(3–5), we observed that 20 out of 21 (95%) MMR-d cancers with genomic inactiv...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, Natasja L., van de Haar, Joris, Veninga, Vivien, Chalabi, Myriam, Ijsselsteijn, Marieke E., van der Ploeg, Manon, van den Bulk, Jitske, Ruano, Dina, van den Berg, Jose G., Haanen, John B., Zeverijn, Laurien J., Geurts, Birgit S., de Wit, Gijs F., Battaglia, Thomas W., Gelderblom, Hans, Verheul, Henk M. W., Schumacher, Ton N., Wessels, Lodewyk F. A., Koning, Frits, de Miranda, Noel F. C. C., Voest, Emile E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876799/
https://www.ncbi.nlm.nih.gov/pubmed/36631610
http://dx.doi.org/10.1038/s41586-022-05593-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876799/
https://www.ncbi.nlm.nih.gov/pubmed/36631610
http://dx.doi.org/10.1038/s41586-022-05593-1

Ejemplares similares